First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Pheon Therapeutics
Seagen Inc.
Blueprint Medicines Corporation
Alaunos Therapeutics
Tempus AI
Incyte Corporation
NiKang Therapeutics, Inc.
Bolt Biotherapeutics, Inc.
Pfizer
Alaunos Therapeutics
NuCana plc
Pfizer
Ohio State University Comprehensive Cancer Center
Seagen Inc.
Seagen Inc.
Aminex Therapeutics, Inc.
pharmaand GmbH
Fate Therapeutics
Zai Lab (Hong Kong), Ltd.
Incyte Corporation
CureOne
Novartis
Calando Pharmaceuticals
National Cancer Institute (NCI)